• Issues
    • Current Issue
    • Special Issues
  • Viewpoints
    • Editor’s Corner
    • Advanced Practice Voices
    • From Our Readers
      • You Make the Call: Readers’ Response
      • Guest Commentary
      • Letters to the Editor
    • A Day in the Life
    • Notes From the Hill
    • The Break Room
  • Education
    • You Make the Call
    • Hematologica Obscura
    • How I Teach
    • How I Treat In Brief
    • Demystifying the Lab
    • Practice Update
  • Spotlight
    • Feature Articles
    • Pulling Back the Curtain
    • Blood Beyond Borders
    • pASHions
    • Drawing First Blood
    • HemOnc Link
    • Interviews
  • News
    • Online Exclusives
    • Latest & Greatest
    • From the Blood Journals
      • Written in Blood
      • Blood Advances in a Different Vein
    • Literature Scan
    • ASH Directions
    • The Society Pages
  • Topic Compilations
    • COVID-19 News
    • Acute Leukemias
    • Chronic Leukemias
    • MDS & Myeloproliferative Neoplasms
    • Multiple Myeloma & Plasma Cell Disorders
    • Lymphomas & Lymphoid Neoplasia
    • Bleeding Disorders
    • Clotting Disorders
    • Red Blood Cell & Iron Disorders
  • On Location
    • ASH Annual Meeting
    • ASH Meeting on Hematologic Malignancies
    • ASH Meeting on Lymphoma Biology
    • Other Meetings
  • Multimedia
    • Sound Bites
    • Meeting Coverage
Search
  • ASH Home
  • About ASH Clinical News
  • Authors
  • Advertising
  • Subscribe
  • Contact Us
  • eNewsletters
  • Cookie Settings
  • LOG IN
Welcome! Log into your account
Forgot your password?
Recover your password
ASH Clinical News
  • Issues
    • AllCurrent IssueSpecial Issues

      April 2021 Volume 7 Issue 5

      March 2021 Special Edition

      March 2021 Volume 7 Issue 4

      February 2021 Volume 7 Issue 3

  • Viewpoints
    • Editor’s Corner
    • Advanced Practice Voices
    • From Our Readers
      • You Make the Call: Readers’ Response
      • Guest Commentary
      • Letters to the Editor
    • A Day in the Life
    • Notes From the Hill
    • The Break Room
  • Education
    • You Make the Call
    • Hematologica Obscura
    • How I Teach
    • How I Treat In Brief
    • Demystifying the Lab
    • Practice Update
  • Spotlight
    • Feature Articles
    • Pulling Back the Curtain
    • Blood Beyond Borders
    • pASHions
    • Drawing First Blood
    • HemOnc Link
    • Interviews
  • News
    • Online Exclusives
    • Latest & Greatest
    • From the Blood Journals
      • Written in Blood
      • Blood Advances in a Different Vein
    • Literature Scan
    • ASH Directions
    • The Society Pages
  • Topic Compilations
    • COVID-19 News
    • Acute Leukemias
    • Chronic Leukemias
    • MDS & Myeloproliferative Neoplasms
    • Multiple Myeloma & Plasma Cell Disorders
    • Lymphomas & Lymphoid Neoplasia
    • Bleeding Disorders
    • Clotting Disorders
    • Red Blood Cell & Iron Disorders
  • On Location
    • ASH Annual Meeting
    • ASH Meeting on Hematologic Malignancies
    • ASH Meeting on Lymphoma Biology
    • Other Meetings
  • Multimedia
    • Sound Bites
    • Meeting Coverage
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Home Multimedia Exclusive Videos
  • Exclusive Videos
  • Lymphomas & Lymphoid Neoplasia
  • Meeting Coverage
  • Multimedia

John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma

Monday, June 8, 2020

Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III KEYNOTE-204 trial.

SHARE
Sabrina Ahle
Advertisement

Recent Articles

European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma

Sunday, April 11, 2021
Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...

FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma

Sunday, April 11, 2021
Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...

Countries Restrict AstraZeneca Vaccine for Younger Adults

Sunday, April 11, 2021
Amid concerns over clotting risks, German and Canadian health officials have restricted usage of the AstraZeneca COVID-19 vaccine in people under the age of...

Investigation Finds Hemophilia Gene Therapy Likely Did Not Cause Hepatocellular Carcinoma

Sunday, April 11, 2021
An investigation found that etranacogene dezaparvovec was unlikely to have caused a case of hepatocellular carcinoma (HCC) in a participant of the HOPE-B trial,...

Daunorubicin and Cytarabine Combination Approved for Pediatric Secondary AML

Sunday, April 11, 2021
The U.S. Food and Drug Administration (FDA) has approved a revised label for liposomal daunorubicin and cytarabine, CPX 351, to include a new indication...

Current Issue

April 2021 Volume 7 Issue 5

Thursday, April 1, 2021
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.
Related Articles
Recent Posts
  • European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma
  • FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma
  • Countries Restrict AstraZeneca Vaccine for Younger Adults
  • Investigation Finds Hemophilia Gene Therapy Likely Did Not Cause Hepatocellular Carcinoma

Meeting Coverage

Researchers Validate Burkitt Lymphoma Prognostic Index

Monday, March 1, 2021

Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL

Monday, March 1, 2021

Editor's Corner

Editor’s Corner: Post-Pandemia Mania

Thursday, April 1, 2021

Editor’s Corner: Healing Our Invisible Wounds

Monday, March 1, 2021
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
  • ASH Home
  • Research
  • Education
  • Advocacy
  • Meetings
  • Publications
  • ASH Store
Copyright © 2020 by American Society of Hematology

Contact Us | Terms of Service | Privacy Policy